Specialty pharmaceutical manufacturers, which typically produce low-volume, high-value drugs, such as medicines for rare diseases and cell and gene therapies, are facing expanded product verification requirements under the final phase of the U.S. Drug Supply Chain Security Act (DSCSA).

In this article, we’ll explain why specialty drug manufacturers need a product verification solution even if they do not accept returns, do not expect to be part of suspect product investigations, and do not expect a high number of product verification requests.

We’ll also explain why TraceLink Product Information Manager – Product Verification, a proven digital network-based product verification solution that provides responses to product verification requests from direct and indirect trade partners in less than one second, is the fastest, most effective, and most cost-efficient way to comply with these requirements. Read more >